Russia · Delayed Price · Currency is RUB Pharmsynthez Statistics
Total Valuation
Pharmsynthez has a market cap or net worth of RUB 1.36 billion. The enterprise value is 2.05 billion.
| Market Cap | 1.36B |
| Enterprise Value | 2.05B |
Important Dates
The next estimated earnings date is Friday, May 7, 2027.
| Earnings Date | May 7, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmsynthez has 301.01 million shares outstanding. The number of shares has increased by 1.90% in one year.
| Current Share Class | 301.01M |
| Shares Outstanding | 301.01M |
| Shares Change (YoY) | +1.90% |
| Shares Change (QoQ) | +26.69% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 25.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.80 |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.29, with a Debt / Equity ratio of 0.27.
| Current Ratio | 0.29 |
| Quick Ratio | 0.22 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.34 |
Financial Efficiency
Return on equity (ROE) is -15.95% and return on invested capital (ROIC) is -4.43%.
| Return on Equity (ROE) | -15.95% |
| Return on Assets (ROA) | -3.61% |
| Return on Invested Capital (ROIC) | -4.43% |
| Return on Capital Employed (ROCE) | -8.98% |
| Weighted Average Cost of Capital (WACC) | 4.59% |
| Revenue Per Employee | 3.38M |
| Profits Per Employee | -4.87M |
| Employee Count | 59 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.90 |
Taxes
In the past 12 months, Pharmsynthez has paid 126.48 million in taxes.
| Income Tax | 126.48M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.60% in the last 52 weeks. The beta is 0.02, so Pharmsynthez's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -24.60% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 5.11 |
| Relative Strength Index (RSI) | 63.97 |
| Average Volume (20 Days) | 9,839,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmsynthez had revenue of RUB 199.43 million and -287.39 million in losses. Loss per share was -0.64.
| Revenue | 199.43M |
| Gross Profit | 73.96M |
| Operating Income | -156.14M |
| Pretax Income | -160.91M |
| Net Income | -287.39M |
| EBITDA | -127.19M |
| EBIT | -156.14M |
| Loss Per Share | -0.64 |
Balance Sheet
The company has 1.54 million in cash and 440.84 million in debt, with a net cash position of -439.30 million or -1.46 per share.
| Cash & Cash Equivalents | 1.54M |
| Total Debt | 440.84M |
| Net Cash | -439.30M |
| Net Cash Per Share | -1.46 |
| Equity (Book Value) | 1.66B |
| Book Value Per Share | 3.40 |
| Working Capital | -615.85M |
Cash Flow
In the last 12 months, operating cash flow was -20.72 million and capital expenditures 672,000, giving a free cash flow of -20.05 million.
| Operating Cash Flow | -20.72M |
| Capital Expenditures | 672,000 |
| Depreciation & Amortization | 28.95M |
| Net Borrowing | 6.82M |
| Free Cash Flow | -20.05M |
| FCF Per Share | -0.07 |
Margins
Gross margin is 37.08%, with operating and profit margins of -78.29% and -144.10%.
| Gross Margin | 37.08% |
| Operating Margin | -78.29% |
| Pretax Margin | -80.68% |
| Profit Margin | -144.10% |
| EBITDA Margin | -63.78% |
| EBIT Margin | -78.29% |
| FCF Margin | n/a |
Dividends & Yields
Pharmsynthez does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.90% |
| Shareholder Yield | -1.90% |
| Earnings Yield | -14.27% |
| FCF Yield | -1.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |